Home›Search›Immuno-Oncology and Technology

Immuno-Oncology and Technology

Elsevier Inc. · United States · Est. 2019

ISSN2590-0188

SJR Q1✓ Scopus / SJR✓ DOAJ✓ Open Access

Journal Impact Factor

Not on record at PubScope. The Journal Impact Factor is published by Clarivate for Web of Science (JCR)–indexed journals. If this journal has one, it appears on the journal’s page ↗

📊 Standing in its field

Where this journal ranks among others in the same subject area.

SJR · Scopus

Top 25% in field

Clarivate’s JCR quartile is a separate ranking and may differ

SJR Scorei

1.883

H-Indexi

SNIPi

0.962

Total Worksi

1,229

Total Citationsi

1,808

2yr Mean Citednessi

0.27

Open Impact Factor alternative

Aims & Scope

Subject areas: Immunology and Allergy; Oncology.

General Information

Country / RegionUnited States

Primary LanguageEnglish

1st Year Published2019

Annual Volume~ 297 articles / year

StatusActive (last: 2026)

Total Publications1,229

Publisher OrgElsevier BV

OA Since2018

Visit Journal Website

Submission Info

Peer ReviewDouble-blind

OA LicenseCC BY, CC BY-NC-ND

OA Rate—

Ethics & Quality

COPE Member✗ No

OASPA Member✗ No

Not on Predatory Lists✓ Yes

Plagiarism Detection✗ No

📦 Long-term Preservation

PorticoPMCCLOCKSS

Think.Check.Submit Compliance

thinkchecksubmit.org

9/11 · 82%

✅

Do you know the journal / publisher?

Elsevier Inc.

✅

Does the journal have a website?

✓ Linked

✅

Is the ISSN verified?

2590-0188

✅

Indexed in a trusted database?

Scopus, DOAJ, PubMed

✅

Peer review process documented?

Double-blind

❌

Follows ethical publishing standards (COPE)?

N/A

✅

Not on predatory/blacklists?

✓ Clean

✅

Long-term digital preservation?

Portico, PMC, CLOCKSS

❌

Plagiarism detection in place?

✅

Listed in DOAJ (verified OA)?

DOAJ verified

✅

Primary language documented?

English

A twelfth criterion — whether APC fees are clearly disclosed — is not scored here; it is left out of the total rather than counted as a failure. Publication charges appear in the metrics card above.

Based on the Think.Check.Submit framework by DOAJ, COPE & OASPA. All data from verified open sources.

Publication & Citation Trend

Articles published

Citations received

312

2019

214

2020

123

2021

270

717

2022

229

416

2023

255

241

2024

407

2025

2026

Source: OpenAlex · Each year’s green bar = citations earned by that year’s papers, counted to date — so recent years look lower simply because their papers haven’t had time to be cited yet.

SJR Quartile by Discipline

Scimago ranks this journal separately in each subject category — its quartile can differ by discipline.

Immunology and AllergyQ1

OncologyQ1

Subject Classification

Scopus Categories

Immunology and AllergyOncology

Research Topics (OpenAlex)

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCAR-T cell therapy researchLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Genomics and DiagnosticsDiverse Scientific and Economic StudiesColorectal Cancer Treatments and StudiesCancer Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Frequently asked questions about Immuno-Oncology and Technology

Is Immuno-Oncology and Technology a predatory journal?

PubScope has no integrity flags on record for Immuno-Oncology and Technology: it is indexed in Scopus, DOAJ, and is not on DOAJ's withdrawn list. Indexing is a transparency signal, not a guarantee — always confirm fit and policies before submitting.

What is the impact factor of Immuno-Oncology and Technology?

Immuno-Oncology and Technology is not in the Web of Science Core Collection, so it has no official Clarivate Journal Impact Factor. Its SCImago SJR score is 1.883.

Is Immuno-Oncology and Technology indexed in Scopus and Web of Science?

Immuno-Oncology and Technology is indexed in Scopus, DOAJ.

What is the aims and scope of Immuno-Oncology and Technology?